Viatris (VTRS) reported $3.7 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 5%. EPS of $0.57 for the same period compares to $0.54 a year ago.
The reported revenue represents a surprise of +5.29% over the Zacks Consensus Estimate of $3.52 billion. With the consensus EPS estimate being $0.52, the EPS surprise was +9.62%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Viatris performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:View all Key Company Metrics for Viatris here>>>
Shares of Viatris have returned +24% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
This article originally published on Zacks Investment Research (zacks.com).
| 10 hours | |
| Nov-16 | |
| Nov-16 | |
| Nov-12 | |
| Nov-12 | |
| Nov-11 | |
| Nov-11 | |
| Nov-11 | |
| Nov-05 | |
| Nov-05 |
Top 8% Drugmaker Hikes Guidance On The Back Of Its Mixed Third Quarter
VTRS
Investor's Business Daily
|
| Nov-05 | |
| Nov-05 | |
| Nov-04 | |
| Oct-30 | |
| Oct-30 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite